Literature DB >> 31711772

Metabolically healthy obesity (MHO) in the Malmö diet cancer study - Epidemiology and prospective risks.

Johan Korduner1, Erasmus Bachus2, Amra Jujic3, Martin Magnusson4, Peter M Nilsson5.   

Abstract

BACKGROUND/AIMS: Metabolically healthy obesity (MHO) remains controversial, since the underlying mechanisms behind this phenotype remain unclear. We aimed to investigate the characteristics of MHO, as well as prospective risks.
METHOD: A cross-sectional analysis was carried out in a subsample of 3812 obese subjects selected from the Malmo diet cancer study (n=28,403). Subjects with MHO (n=1182) were defined by having no records of hospitalization for somatic disorders prior to baseline examination. MHO subjects were further compared to subjects with metabolically unhealthy obesity, MUO (obese individuals with at least one recorded hospitalization: n=2630), and all non-obese cohort controls (NOC; n=24,591). Moreover, prospective risk analyses for incident cardiovascular (CV) morbidity and mortality were carried out.
RESULTS: Compared to MUO individuals, MHO individuals reported a significantly lower proportion of sedentary life style (p=0.009), but also significantly lower HbA1c (p=0.012), fasting glucose (p=0.001) and triglyceride levels (p=0.011) than MUO. Cox-regression analysis (follow-up 20±6 years) showed both a significantly lower all-cause mortality risk for MHO individuals as compared to MUO (p=0.001), as well as lower incident CV morbidity risk (p=0.001). When comparing MHO individuals to NOC, there were no significant differences in neither mortality risk nor incident CV morbidity risk.
CONCLUSION: Compared to MUO individuals, MHO individuals presented with a higher level of physical activity, a more favorable lipid- and glucose profile and a lower prospective risk of total mortality and CV morbidity during 20-years follow-up. Notably, no significant differences could be seen in mortality and CV morbidity risks when comparing MHO subjects to non-obese controls.
Copyright © 2019 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular; Epidemiology; Metabolic syndrome; Morbidity; Mortality; Obesity

Year:  2019        PMID: 31711772     DOI: 10.1016/j.orcp.2019.10.002

Source DB:  PubMed          Journal:  Obes Res Clin Pract        ISSN: 1871-403X            Impact factor:   2.288


  10 in total

1.  Time-Restricted Feeding Studies and Possible Human Benefit.

Authors:  Patrick Boyd; Sydney G O'Connor; Brandy M Heckman-Stoddard; Edward R Sauter
Journal:  JNCI Cancer Spectr       Date:  2022-05-02

2.  Galectin-4 levels in hospitalized versus non-hospitalized subjects with obesity: the Malmö Preventive Project.

Authors:  Johan Korduner; Hannes Holm; Amra Jujic; Olle Melander; Manan Pareek; John Molvin; Lennart Råstam; Ulf Lindblad; Bledar Daka; Margret Leosdottir; Peter M Nilsson; Erasmus Bachus; Michael H Olsen; Martin Magnusson
Journal:  Cardiovasc Diabetol       Date:  2022-07-02       Impact factor: 8.949

3.  Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and Mortality.

Authors:  Filip Ottosson; Einar Smith; Ulrika Ericson; Louise Brunkwall; Marju Orho-Melander; Salvatore Di Somma; Paola Antonini; Peter M Nilsson; Céline Fernandez; Olle Melander
Journal:  Diabetes Care       Date:  2022-05-01       Impact factor: 17.152

4.  Metabolically Healthy, but Obese Individuals and Associations with Echocardiographic Parameters and Inflammatory Biomarkers: Results from the CARLA Study.

Authors:  Ljupcho Efremov; Maria Elena Lacruz; Daniel Tiller; Daniel Medenwald; Karin Halina Greiser; Alexander Kluttig; Andreas Wienke; Sebastian Nuding; Rafael Mikolajczyk
Journal:  Diabetes Metab Syndr Obes       Date:  2020-07-27       Impact factor: 3.168

5.  Diabetes and kidney cancer risk among post-menopausal women: The Iowa women's health study.

Authors:  Shuo Wang; Mark D Lo Galbo; Cindy Blair; Bharat Thyagarajan; Kristin E Anderson; DeAnn Lazovich; Anna Prizment
Journal:  Maturitas       Date:  2020-08-11       Impact factor: 4.342

6.  Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects.

Authors:  Johan Frostegård; M Magnusson; Amra Jujić; J Korduner; H Holm; G Engström; E Bachus; P Bhattacharya; P M Nilsson
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

Review 7.  The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.

Authors:  José Antônio Fagundes Assumpção; Gabriel Pasquarelli-do-Nascimento; Mariana Saldanha Viegas Duarte; Martín Hernan Bonamino; Kelly Grace Magalhães
Journal:  J Biomed Sci       Date:  2022-02-14       Impact factor: 8.410

8.  Metabolic Obesity Phenotypes and Risk of Lung Cancer: A Prospective Cohort Study of 450,482 UK Biobank Participants.

Authors:  Fang Shao; Yina Chen; Hongyang Xu; Xin Chen; Jiawei Zhou; Yaqian Wu; Yingdan Tang; Zhongtian Wang; Ruyang Zhang; Theis Lange; Hongxia Ma; Zhibin Hu; Hongbing Shen; David C Christiani; Feng Chen; Yang Zhao; Dongfang You
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

Review 9.  Metabolically Healthy Obesity (MHO)-New Research Directions for Personalised Medicine in Cardiovascular Prevention.

Authors:  Peter M Nilsson; Johan Korduner; Martin Magnusson
Journal:  Curr Hypertens Rep       Date:  2020-02-17       Impact factor: 5.369

10.  Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants.

Authors:  Ziyi Zhou; John Macpherson; Stuart R Gray; Jason M R Gill; Paul Welsh; Carlos Celis-Morales; Naveed Sattar; Jill P Pell; Frederick K Ho
Journal:  Diabetologia       Date:  2021-06-10       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.